Mohamed K. Mohamed, MD, PhD, discusses how CIM disrupts treatment, burdens patients, and why a proactive management approach is critical in SCLC care.
Therapies Reducing Adverse Events in Extensive-Stage SCLC
Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.
Trilaciclib reshapes SCLC supportive care by protecting bone marrow from chemo, reducing anemia and thrombocytopenia, and improving treatment tolerance and quality of life.
Explore innovative strategies in small cell lung cancer treatment, focusing on bone marrow protection to enhance patient outcomes and treatment durability.
Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.
During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.
During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced neutropenia in SCLC.